Table 1:

Patient, tumor and LUM015 signal characteristics

Patient	LUM015 dose (mg/kg)	Age (years)	Menopause Status	Breast Density	Tumor Histology	Tumor Grade	Largest Tumor Size (cm)	Tumor: Normal (T:N) Signal Ratio
1	0.0	56	Post	Heterogeneously dense	IDC and DCIS (ER+, PR+, HER2+)	2 to 3	0.06	1.42
2	0.0	73	Post	Scattered areas of fibroglandular density	DCIS (ER+, PR+)	1 to 2	5 of 15 blocks	§
3	0.0	78	Post	Scattered areas of fibroglandular density	ILC (ER+, PR+, HER2−)	2	1.3	2.83
4	0.0	58	Post	Heterogeneously dense	DCIS (ER+, PR+, HER2−)	2	9 of 21 blocks	§
5	0.0	69	Post	Fatty	IDC and DCIS (ER+, PR+, HER2−)	2	1.0	1.9
6	0.5	48	Pre	Heterogeneously dense	Invasive, mixed ductal and lobular features and DCIS (ER+, PR+, HER2−)	1 to 2	1.2	6.48
7	0.5	65	Post	Scattered areas of fibroglandular density	DCIS (ER+, PR+)	2	1.2	3.38
8	0.5	70	Post	Scattered areas of fibroglandular density and heterogeneously dense	IDC and DCIS (ER+, PR+, HER2−)	2	1.9	4.82
9	0.5	56	Post	Heterogeneously dense	IDC and DCIS (ER+, PR+, HER2−)	2	1.8	6.82
10	0.5	65	Post	Heterogeneously dense	IDC and extensive DCIS (ER+, PR+, HER2−)	2 to 3	1.9	1.99
11	1.0	63	Post	Heterogeneously dense	IDC and DCIS (ER+, PR+, HER2−)	1 to 2	0.4	§
12	1.0	48	Pre	Heterogeneously dense	IDC and DCIS (ER+, PR−, HER2−)	3	2.5	5.46
13	1.0	56	Post	Heterogeneously dense	IDC, ILC and DCIS (ER+, PR+, HER2−)	2	1.8	6.37
14	1.0	78	Post	Fatty	DCIS (ER+, PR+)	2	2.4	3.22
15	1.0	59	Post	Heterogeneously dense	IDC and extensive DCIS (ER+, PR+, HER2−)	1 to 2	1.4	1.84

^§Transection data was not collected due to a failure to either obtain fluorescent images or images were taken of sections that did not contain tumor

IDC – invasive ductal cancer, ILC – invasive lobular cancer, DCIS – ductal carcinoma in situ, ER – estrogen receptor, PR – progesterone receptor, HER2 – human epidermal growth factor receptor 2